Exelixis (EXEL) reported Q1 non-GAAP net income late Tuesday of $0.62 per diluted share, up from $0.17 a year earlier.
Analysts polled by FactSet expected $0.44.
Revenue for the quarter ended March 31 was $555.4 million, up from $425.2 million a year earlier.
Analysts polled by FactSet expected $499.6 million.
For full-year 2025, the oncology company increased its revenue guidance to a range of $2.25 billion to $2.35 billion, up from its prior outlook of $2.15 billion to $2.25 billion. Analysts polled by FactSet are looking for $2.25 billion.
Exelixis shares were up more than 6% in Tuesday's after-market activity.
Price: 39.35, Change: +2.40, Percent Change: +6.50
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。